Cargando…

S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY

Detalles Bibliográficos
Autores principales:	Bal, Susan, Berdeja, Jesus, Htut, Myo, Kocoglu, Mehmet, Gregory, Tara, Anderson, Larry D., Rossi, Adriana, Egan, Daniel, Costa, Luciano, Kelly, Lisa, Ziyad, Safiyyah, Hu, Hongxiang, Chen, Yanping, Kaeding, Allison J., Burgess, Michael, Hege, Kristen, Nadeem, Omar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428438/ http://dx.doi.org/10.1097/01.HS9.0000967684.98632.87

Ejemplares similares

S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

circGprc5a Promoted Bladder Oncogenesis and Metastasis through Gprc5a-Targeting Peptide
por: Gu, Chaohui, et al.
Publicado: (2018)

S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Touzeau, Cyrille, et al.
Publicado: (2023)

The emerging roles of GPRC5A in diseases
por: Zhou, Honglei, et al.
Publicado: (2014)

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
por: Lee, Holly, et al.
Publicado: (2023)

GPRC5A: An Emerging Biomarker in Human Cancer
por: Jiang, Xiaoxia, et al.
Publicado: (2018)

Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM
por: Jeryczynski, Georg, et al.
Publicado: (2021)

GPRC5B protects osteoarthritis by regulation of autophagy signaling
por: He, Liang, et al.
Publicado: (2023)

Dapagliflozin: BMS 512148; BMS-512148
Publicado: (2012)

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
por: Xia, Jieyun, et al.
Publicado: (2023)

GPRC5D as a promising therapeutic target in EGFR-wild and immuno-cold non-small cell lung cancer
por: Mei, Jie, et al.
Publicado: (2023)

RhoA/C inhibits proliferation by inducing the synthesis of GPRC5A
por: Richter, Lukas, et al.
Publicado: (2020)

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
por: Zhao, Juanjuan, et al.
Publicado: (2023)

EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung cancer
por: Lin, Xiaofeng, et al.
Publicado: (2014)

miR-342 inhibits glioma cell proliferation by targeting GPRC5A
por: Wang, Jianjiao, et al.
Publicado: (2019)

Orphan G-Protein Coupled Receptor GPRC5B Is Critical for Lymphatic Development
por: Xu, Wenjing, et al.
Publicado: (2022)

Hyaluronic acid–GPRC5C signalling promotes dormancy in haematopoietic stem cells
por: Zhang, Yu Wei, et al.
Publicado: (2022)

Aquaporin-4 and GPRC5B: old and new players in controlling brain oedema
por: Passchier, Emma M J, et al.
Publicado: (2023)

MiR-103a-3p targets the 5′ UTR of GPRC5A in pancreatic cells
por: Zhou, Honglei, et al.
Publicado: (2014)

P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.
por: Vesole, David H., et al.
Publicado: (2023)

Cases Reported by Surgeon R. D. Murray, M.B. B.M.S.
Publicado: (1878)

P825: SOLUBLE FACTORS CORRELATED WITH CYTOKINE RELEASE SYNDROME (CRS) WITH IV VS SUBCUTANEOUS (SC) ALNUCTAMAB (ALNUC; BMS-986349; CC-93269) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
por: Boss, Isaac, et al.
Publicado: (2023)

Cancer cell adaptation to hypoxia involves a HIF‐GPRC5A‐YAP axis
por: Greenhough, Alexander, et al.
Publicado: (2018)

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US
por: Davies, Faith, et al.
Publicado: (2021)

P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RESULTS FROM MONUMENTAL-1
por: van de Donk, N. W. C. J, et al.
Publicado: (2022)

Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529
por: Pancera, Marie, et al.
Publicado: (2017)

Enhancement of lung tumorigenesis in a Gprc5a Knockout mouse by chronic extrinsic airway inflammation
por: Barta, Peter, et al.
Publicado: (2012)

GPRC5A suppresses protein synthesis at the endoplasmic reticulum to prevent radiation-induced lung tumorigenesis
por: Wang, Jian, et al.
Publicado: (2016)

Prognostic and clinicopathological significance of GPRC5A in various cancers: A systematic review and meta-analysis
por: Dai, Lu, et al.
Publicado: (2021)

GPRC5A: An emerging prognostic biomarker for predicting malignancy of Pancreatic Cancer based on bioinformatics analysis
por: Qian, Xuetian, et al.
Publicado: (2021)

IMUP and GPRC5A: two newly identified risk score indicators in pancreatic ductal adenocarcinoma
por: Wei, Rong, et al.
Publicado: (2021)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

Barrel-muon-spectrometer: BMS
Publicado: (2005)

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (MONUMENTAL-1)
por: Minnema, M.C., et al.
Publicado: (2023)

FABP4 inhibitors 3D-QSAR model and isosteric replacement of BMS309403 datasets
por: Floresta, Giuseppe, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f8ueiqhav9tk1bfku3jgtkbbmj